Form 8-K - Current report:
SEC Accession No. 0001104659-21-088968
Filing Date
2021-07-02
Accepted
2021-07-02 17:02:15
Documents
12
Period of Report
2021-06-30
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2121317d1_8k.htm   iXBRL 8-K 25087
  Complete submission text file 0001104659-21-088968.txt   201450

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vyne-20210630.xsd EX-101.SCH 3215
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20210630_lab.xml EX-101.LAB 34593
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20210630_pre.xml EX-101.PRE 22730
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2121317d1_8k_htm.xml XML 3712
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 211071164
SIC: 2834 Pharmaceutical Preparations